Thioredoxin and Its Potential Therapeutic Applications (G7296)

Target Name: TXNRD1

NCBI ID: G7296

TXNRD1

Thioredoxin and Its Potential Therapeutic Applications

Thioredoxin (Thx) is a protein that plays a crucial role in cellular metabolism and homeostasis. It is a cytoplasmic protein that is involved in the detoxification of xenobiotics, such as bacterial and viral toxins, as well as other harmful substances. The thioredoxin gene (TXNRD1) has been identified as a potential drug target in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The TXNRD1 gene

The TXNRD1 gene is located on chromosome 6p21.2 and encodes a protein known as thioredoxin reductase GRIM-12 (TXRDGRIM-12). This protein is involved in the reduction of thioredoxin to its active form, which is toxic to pathogens and other harmful substances.

Thioredoxin is a small molecule that plays a central role in the detoxification of xenobiotics and other harmful substances. It is a cytoplasmic protein that is composed of 26 amino acid residues. It has a molecular weight of 34 kDa and a pre-protein structure of 38 kDa. Thioredoxin is involved in the detoxification of a wide variety of xenobiotics, including bacterial and viral toxins, as well as other harmful substances.

Thioredoxin detoxification is a critical process for maintaining cellular homeostasis. It is involved in the detoxification of a wide variety of xenobiotics, including bacterial and viral toxins, as well as other harmful substances. Thioredoxin detoxification is also involved in the regulation of cellular signaling pathways, including the production of reactive oxygen species (ROS) and the detoxification of reactive oxygen species.

Thioredoxin reductase (TXRD) is a enzyme that is involved in the detoxification of thioredoxin. It is a cytoplasmic protein that is composed of 26 amino acid residues. It has a molecular weight of 34 kDa and a pre-protein structure of 38 kDa. TXRD is involved in the reduction of thioredoxin to its active form, which is toxic to pathogens and other harmful substances.

TXRDGRIM-12 is a protein that is composed of the full-length coding of the TXRD gene. It is a cytoplasmic protein that is involved in the detoxification of thioredoxin. It has a molecular weight of 61 kDa and a pre-protein structure of 63 kDa. TXRDGRIM-12 is involved in the reduction of thioredoxin to its active form, which is toxic to pathogens and other harmful substances.

Drug targeting TXNRD1

TXNRD1 is a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The development of inhibitors of TXNRD1 has the potential to treat a wide range of diseases.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, the production of thioredoxin is defective, leading to the accumulation of toxic thioredoxin species in the brain. The development of inhibitors of TXNRD1 has the potential to treat these diseases.

In cancer, the production of thioredoxin is often increased, leading to the accumulation of toxic thioredoxin species in the cells. The development of inhibitors of TXNRD1 has the potential to treat various types of cancer.

In autoimmune disorders, the production of thioredoxin is often increased, leading to the accumulation of toxic thioredoxin species in the cells. The development of inhibitors of TXNRD1 has the potential to treat

Protein Name: Thioredoxin Reductase 1

Functions: Reduces disulfideprotein thioredoxin (Trx) to its dithiol-containing form (PubMed:8577704). Homodimeric flavoprotein involved in the regulation of cellular redox reactions, growth and differentiation. Contains a selenocysteine residue at the C-terminal active site that is essential for catalysis (Probable). Also has reductase activity on hydrogen peroxide (H2O2) (PubMed:10849437)

The "TXNRD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TXNRD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets